Stockscreener 앱 받기
14.06
3.43%
-0.50
시장 영업 전:
14.65
0.59
+4.20%
Amarin Corp Adr 주식(AMRN)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
Amarin shareholders reject key proposals at annual meeting, limit equity grants - Investing.com
AMRN Technical Analysis | Trend, Signals & Chart Patterns | AMARIN CORP PLC -ADR (NASDAQ:AMRN) - ChartMill
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales - TradingView
Amarin (AMRN) Loss Trend Of 24.2% Annually Tests Turnaround Narratives Heading Into Q1 - Sahm
Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs - ChartMill
Amarin Corp PLC (FRA:EH3) Stock Price, Trades & News - GuruFocus
Amarin Corporation Plc Sponsored ADR Trade Ideas — FWB:EH3 - TradingView
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks - The Motley Fool
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz
Amarin Corporation Plc Sponsored ADR Trade Ideas — SWB:EH3 - TradingView
Amarin (NASDAQ: AMRN) details VASCEPA reach, Recordati deal and $70M savings - Stock Titan
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss - Finviz
Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 - ChartMill
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Finviz
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - Finviz
China Universal Asset Management Co. Ltd. Sells 76,302 Shares of Amarin Corporation PLC $AMRN - Defense World
Net current asset value per share of Amarin Corporation Plc Sponsored ADR – MUN:EH3 - TradingView — Track All Markets
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth - Sahm
Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight - Law360
Tops & Flops Stocks - sharewise.com
Amarin (AMRN) Unprofitable as Losses Worsen, Profit Growth Forecasts Test Bullish Turnaround Hopes - Sahm
Leerink Partners raises Amarin stock price target to $12 on strong Q3 - Investing.com
FDA updates fenofibrate labels to reflect lack of cardiovascular benefit - Investing.com
Amarin stock rises after ESC Congress data on VASCEPA mechanism - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect - Finviz
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Finviz
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - Finviz
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin stock jumps after $25 million licensing deal with Recordati - Investing.com
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Finviz
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease - Finviz
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Finviz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines - Finviz
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Finviz
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies - Finviz
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
Global X Aging Population ETF Holdings - Quiver Quantitative
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
China approves VASCEPA to reduce cardiovascular risk - Investing.com
What's going on in today's pre-market session - ChartMill
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
Earnings BeforeStock ScreenerSnapshot - Finviz
Amarin CorpADR (AMRN) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Amarin (AMRN) - Zacks Investment Research
What date does Amarin's (AMRN) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Generic-Drug Labeling Strategy Likely to Survive Teva Rehearing - Bloomberg.com
Amarin Stock Melts Down After Losing Patent Battle For Heart Drug - Investor's Business Daily
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval - MarketWatch
This Biotech Stock Just Got A Highly Anticipated FDA Approval - Investor's Business Daily
Lone Mallinckrodt Bull Undaunted After Share Price Tumbles 94% - Bloomberg.com
This IBD Stock Of The Day Expects An FDA Approval To Send Sales Flying - Investor's Business Daily
62 Stocks Doubled In 2018 - Investing.com
Amarin Surges on Fish-Oil Drug Data - WSJ
Investors Are Undervaluing Amarin Corporation plc (NASDAQ:AMRN) By 26.89% - simplywall.st
3 Stocks That Could Put Tesla's Returns to Shame - The Motley Fool
10 Cheap Stocks to Buy With Only $12 - Nasdaq
0.00%
0.59%
자본화:
|
볼륨(24시간):